Get the Stockscreener App
3.0983
4.62%
0.1368
Galecto Inc stock is traded at $3.0983, with a volume of 8,928.
It is up +4.62% in the last 24 hours and up +12.67% over the past month.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
See More
Previous Close:
$2.9615
Open:
$2.9
24h Volume:
8,928
Relative Volume:
0.04
Market Cap:
$4.09M
Revenue:
-
Net Income/Loss:
$-38.35M
P/E Ratio:
-2.1368
EPS:
-1.45
Net Cash Flow:
$-36.91M
1W Performance:
+7.58%
1M Performance:
+12.67%
6M Performance:
-44.87%
1Y Performance:
-80.16%
1-Day Range:
$2.8619
$3.0983
1-Week Range:
$2.665
$3.17
52-Week Range:
$2.01
$16.07
Galecto Inc Stock (GLTO) Company Profile
Name
Galecto Inc
Sector
Industry
Phone
45-70-70-52-10
Address
75 STATE STREET, BOSTON
Compare GLTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
3.0983 | 3.85M | 0 | -38.35M | -36.91M | -1.45 |
|
ONC
Beigene Ltd Adr
|
241.99 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.45 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.67 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.52 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
Galecto Inc Stock (GLTO) Latest News
Galecto Reports First Quarter 2025 Operating and Financial Resul - GuruFocus
Galecto Reports First Quarter 2025 Operating and Financial Results - The Manila Times
Galecto Reports First Quarter 2025 Operating and Financial Results | GLTO Stock News - GuruFocus
Renaissance Technologies LLC Sells 6,338 Shares of Galecto, Inc. (NASDAQ:GLTO) - Defense World
Keppel DC REIT (OTCMKTS:KPDCF) Short Interest Up 133.4% in March - Defense World
Galecto, Inc. (NASDAQ:GLTO) Short Interest Up 133.6% in March - Defense World
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - benzinga.com
Galecto, Inc. Focuses on Oncology and Liver Diseases - TipRanks
Galecto stock hits 52-week low at $3.75 amid market challenges - Investing.com
Galecto stock hits 52-week low at $3.75 amid market challenges By Investing.com - Investing.com South Africa
Galecto stock hits 52-week low at $4.39 amid market challenges - MSN
Pre-market Movers: OSRH, SURG, BLNE, HUMA, TNON… - RTTNews
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Galecto (GLTO) Shares Rally Amid Positive Market Momentum - Stocks Telegraph
Galecto Reports Full-Year 2024 Financial Results - The Manila Times
Galecto Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Galecto, Inc. Completes Strategic Review, Acquires Global Rights to GB3226 for Oncology and Liver Disease Focus - Nasdaq
Galecto Cuts Losses by $17M, Acquires Promising AML Drug Candidate - StockTitan
Galecto Inc expected to post a loss of $2.97 a shareEarnings Preview - TradingView
Idiopathic Pulmonary Fibrosis Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approvals, Therapies, Mechanism of Action, Route of Administration & Companies by DelveInsight - The Globe and Mail
Galecto stock plunges to 52-week low at $3.76 amid market challenges - Investing.com Australia
Galecto stock plunges to 52-week low at $3.76 amid market challenges By Investing.com - Investing.com South Africa
Galecto (GLTO) Projected to Post Quarterly Earnings on Friday - Defense World
Mustang Bio Stock Price, Quotes and Forecasts | NASDAQ:MBIO - Benzinga
Galecto stock hits 52-week low at $4.20 amid market challenges - Investing.com Australia
Galecto stock hits 52-week low at $4.20 amid market challenges By Investing.com - Investing.com South Africa
Eterna Therapeutics (NASDAQ:ERNA) & Galecto (NASDAQ:GLTO) Head to Head Comparison - Defense World
Reviewing Eton Pharmaceuticals (NASDAQ:ETON) & Galecto (NASDAQ:GLTO) - Defense World
Galecto to Participate in Upcoming Investor Conferences - The Globe and Mail
Galecto stock hits 52-week low at $4.39 amid market challenges By Investing.com - Investing.com South Africa
Leerink Partnrs Estimates Galecto FY2024 Earnings - Defense World
Brokers Set Expectations for Galecto FY2029 Earnings - Armenian Reporter
Galecto to Participate in Upcoming Investor Conferences -February 06, 2025 at 08:01 am EST - Marketscreener.com
Biotech Spotlight: Galecto Lines Up Triple Conference Showcase for Investors - StockTitan
Where are the Opportunities in (GLTO) - Stock Traders Daily
Sunshine Biopharma (NASDAQ:SBFM) Stock Quotes, Forecast and News Summary - Benzinga
Critical Analysis: Galecto (NASDAQ:GLTO) vs. ObsEva (NASDAQ:OBSV) - Defense World
(GLTO) On The My Stocks Page - Stock Traders Daily
Galecto Inc Stock (GLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galecto Inc Stock (GLTO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Firmani Lori | Interim CFO |
Jan 03 '25 |
Sale |
5.63 |
261 |
1,469 |
465 |
| Schambye Hans T. | Chief Executive Officer |
Jan 03 '25 |
Sale |
5.60 |
1,341 |
7,510 |
3,397 |
17.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):